FDA clearances behind aesthetic devices — and Korea's rise

The laser in your dermatologist's office, the RF microneedling device at the med spa, the IPL handset marketed for home use — every one of these reached the US market through an FDA 510(k) clearance. The 510(k) database is the public record of who submitted the application, where the manufacturer is based, and when the device was cleared.

An analysis of FDA 510(k) records across aesthetic and cosmetic device product codes reveals 4,741 clearances dating back to 1976. The data shows a market long dominated by US manufacturers but now being reshaped by two Asian manufacturing powers: China, which has surged to 10.1% of all aesthetic clearances, and South Korea, whose growth trajectory tells a more nuanced story of premium-device specialization.

This article breaks down the clearance data by device type, manufacturer country, and year — and explains what it means for providers evaluating capital equipment and patients asking where their treatment technology comes from.

How the analysis was built

The FDA 510(k) database contains over 174,000 records for all medical device types. For this analysis, records were filtered to product codes classified under the "General, Plastic Surgery" and "Physical Medicine" advisory panels that correspond to aesthetic and cosmetic devices — including cosmetic lasers (GEX), IPL devices (ONF, OHT), LED and light-therapy devices (OHS, ONE), RF energy devices (PBX, OLI), microneedling devices (QAI), body-contouring platforms (PKT, QPB, OOK), cryolipolysis systems (OOK), hair-restoration devices (OAP), and UV/tanning devices (FTC, LEJ), among others.

This produced 4,741 clearance records spanning 1976 through early 2026. Each record includes the applicant (manufacturer), country code, product code, device name, and decision date.

What the device landscape looks like

The 4,741 aesthetic-device clearances break down into these sub-categories:

General cosmetic lasers — the broad GEX product code that includes everything from Q-switched Nd:YAG systems to picosecond platforms to diode treatment devices — account for nearly half of all clearances. The high count reflects both the longevity of the category (clearances since the 1970s) and the iterative nature of laser-platform development, where each new wavelength, handpiece, or software update often requires a separate 510(k).

Country of origin: US leads, China surges, Korea climbs

Clearances by manufacturer country code:

The US dominance reflects the historical center of aesthetic-device innovation: Cynosure (94 clearances), Sharplan Lasers (66), Laserscope (49), Candela (47), Lumenis US (36), Cutera (28), and Palomar (24) are among the most prolific US applicants. Many of these companies are now subsidiaries of global conglomerates — Cynosure belongs to Hologic, Candela to Apax Partners — but their 510(k) legacy remains US-based.

Israel's strong showing (3.2%) comes from Syneron Medical (23 clearances, now part of Candela), Lumenis (18), InMode (12), and Home Skinovations (12) — a cluster of energy-based-device companies built around RF and laser technology. Italy's position (3.0%) is anchored by Quanta System (57 clearances) and El.En Group (26), both focused on aesthetic laser platforms.

China: volume, not premium (yet)

China's 477 clearances make it the second-largest source country — but the composition differs from the US or Korea:

Chinese manufacturers concentrate in IPL (143 of 229 total IPL clearances, or 62.4%), LED devices (61 of 144, or 42.4%), and diode lasers (54 of 196, or 27.6%). These are the price-competitive segments — at-home IPL hair removal, consumer LED masks, tabletop diode platforms — where lower manufacturing cost translates into significant market share.

China's growth has been exponential: from 5 aesthetic clearances in 2014 to 125 in 2025 alone. The trajectory suggests continued volume growth, particularly in consumer-facing and mid-tier professional devices.

South Korea: premium specialization

South Korea's 127 aesthetic clearances tell a different story from China's. Korea's first aesthetic-device 510(k) clearance came in 2010. By 2025, the country had reached 17 annual clearances — still far fewer than China's 125 but concentrated in higher-value segments.

Top Korean applicants by clearance count:

Korea's device-type distribution:

Several patterns stand out:

1. Picosecond lasers. Korea holds 17 of the 54 total picosecond clearances (31.5%) — a disproportionate share for a country with 2.7% of total clearances. Korean manufacturers like Wontech (PICOHI), Bison Medical (TRI-BEAM), and Hironic have focused on the picosecond segment, which commands premium pricing and is among the fastest-growing technology segments in aesthetic medicine.

2. Established laser brands. Lutronic — one of the most recognized Korean names in US dermatology — has 9 clearances including the eCO2 Plus fractional CO2 laser and the Spectra series. Lutronic's platforms are used in thousands of US clinics for skin resurfacing, pigmentation treatment, and tattoo removal.

3. RF microneedling. Jeisys Medical, a Korean company, developed the technology behind the Secret RF platform now marketed by Cutera in the United States. Wontech's Secret Duo is another Korean-developed RF microneedling device with FDA clearance. The "Korean RF microneedling" pipeline is significant — even when the end-brand marketed in the US is American.

The year-over-year picture

The annual clearance data by country shows how the market has shifted:

Three trends are visible:

• US decline in share. US clearances have dropped from 74% of the annual total in 2010 to 18% in 2025 — not because US companies stopped innovating, but because the total number of applicants from other countries has grown dramatically.
• China's surge. From 4 clearances in 2010 to 125 in 2025, driven by at-home IPL, LED, and consumer devices.
• Korea's steady climb. From zero in 2009 to a consistent 13–18 annual clearances since 2017, concentrated in professional-grade lasers and RF.

What the top US applicants built

The US still holds the largest single-country portfolio, and the top applicants are the names most patients and providers recognize:

Many of these legacy applicants have been acquired, merged, or rebranded. The Cynosure portfolio now sits inside Hologic. Candela absorbed Syneron and Palomar technologies. Lumenis moved from Israel to US incorporation and is now part of Boston Scientific. The 510(k) records capture the original applicant at the time of clearance.

What this means for providers

Evaluating new devices

The country-of-origin data is not a quality proxy — a Korean picosecond laser may be as clinically effective as a US-made one. But it does matter for:

• Service and support infrastructure. US-based manufacturers typically have larger US service teams. Devices from Chinese or Korean manufacturers may rely on third-party distributors, which affects response time when a device needs repair.
• Regulatory history. A manufacturer with 20+ clearances has more 510(k) experience and a longer FDA track record than a company with one or two. Wontech's 25 clearances, for example, indicate sustained engagement with the FDA process.
• Capital equipment decisions. Chinese-manufactured IPL and diode platforms are often priced 30–50% below US or Korean equivalents. For a practice considering a second device for high-volume hair removal, the cost savings may be significant — but the provider should verify post-sale support and consumable availability.

For patients

If your provider uses a Korean-manufactured device (Lutronic Spectra for pigmentation, for instance, or a Wontech platform for RF microneedling), this is not a safety concern. The device cleared the same FDA 510(k) process as every other aesthetic device. The Korean MFDS (Ministry of Food and Drug Safety) also maintains its own device-approval system, and many Korean devices are cleared by both agencies.

The more relevant question is not where the device was made but who is operating it and whether they are trained on that specific platform.

A note on clearance vs. safety

The 510(k) pathway requires substantial equivalence to a predicate device — not new clinical trials. A 2023 analysis published in PMC reviewing device recalls in the General and Plastic Surgery panel found that devices cleared through 510(k) were 5.32 times more likely to be recalled than devices approved through the more rigorous PMA (Premarket Approval) pathway (Shah et al., 2023). Among the most-recalled 510(k) device types in this panel: electrosurgical instruments (22.7% of recalls) and powered laser surgical instruments (9.1%).

This does not mean 510(k) devices are unsafe. Most aesthetic devices are Class II and cleared through 510(k) because the FDA has determined the pathway is appropriate for that device type. But the recall data reinforces why the FDA's October 2025 safety communication on RF microneedling devices — and the broader regulatory conversation around aesthetic-device oversight — carries weight: the 510(k) system was designed for incremental innovation, and its safety net depends heavily on post-market surveillance and adverse-event reporting.

The competitive landscape is shifting

The data shows a market in transition. In 2010, 75% of aesthetic-device clearances went to US applicants. By 2025, that share had fallen to 18%. The decline does not reflect US innovation stalling — it reflects a globalizing industry where manufacturers from China, Korea, Israel, and Italy are all competing for the same US clinic market.

South Korea's trajectory is particularly notable because of its concentration in premium segments. With 31.5% of all picosecond-laser clearances, a growing RF microneedling portfolio, and established brands like Lutronic and Wontech that are already present in US clinics, Korea is moving from "competing on price" to "competing on technology" — and the 510(k) data reflects that shift.

Sources

• FDA 510(k) Premarket Notification Database. Analysis of public 510(k) clearance records for aesthetic and cosmetic device product codes; analysis run date 2026-06-09. accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm
• FDA. "Cleared 510(k) Submissions with Supporting Documents." fda.gov/vaccines-blood-biologics/substantially-equivalent-510k-device-information
• Wispro Consulting. "2025 Q1 FDA 510(k) Clearances: Market Opportunities and Strategic Signals." wispro.com/en/whos-leading-the-pack-whos-catching-up-2025-q1-fda-510k-clearances
• Mordor Intelligence. "South Korea Aesthetic Devices Market Analysis." 2026. mordorintelligence.com/industry-reports/south-korea-aesthetic-devices-market
• Intuition Labs. "FDA 510(k) Explained: Medical Device Premarket Notification Process." intuitionlabs.ai/articles/fda-510k-premarket-notification-process
• Coherent Market Insights. "Medical Aesthetic Devices Market Share & Forecast, 2026–2033." coherentmarketinsights.com/market-insight/medical-aesthetic-devices-market-5336
• PMC. "Review of approvals and recalls of US specific medical devices in general and plastic surgery." Shah et al., 2023. pmc.ncbi.nlm.nih.gov/articles/PMC11749930